Clinical Drug Investigation

, Volume 17, Issue 5, pp 407–410 | Cite as

Pharmacoeconomic Analysis of Intravenous Push vs Slow Infusion of β-Lactam Antibiotics

  • Paul G. Ambrose
  • Khanh Q. Bui
  • Mark A. Richerson
  • Richard Quintiliani
  • Charles Nightingale
Short Communication

Keywords

Adis International Limited Cefotaxime Meropenem Cefazolin Famotidine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ambrose PG, Quintiliani R, Nightingale CH. Pharmacoeconomic analysis of famotidine iv push vs intermittent slow infusion. Ann Pharmacother 1997; 31: 645PubMedGoogle Scholar
  2. 2.
    Vogelman B, Gudmundson S, Leggett J, et al. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 1988; 158: 831–47PubMedCrossRefGoogle Scholar
  3. 3.
    Leggett J, Fantin B, Ebert S, et al. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J Infect Dis 1989; 159: 281–92PubMedCrossRefGoogle Scholar
  4. 4.
    Onyeji CO, Nicolau DP, Nightingale CH, et al. Optimal times about MICs of cefitbuten and cefaclor in experimental intraabdominal infections. Antimicrob Agents Chemother 1994; 38: 1112–7PubMedCrossRefGoogle Scholar
  5. 5.
    Norrby SR, Newell PA, Faulkner KL, et al. Safety profile of meropenem: international clinical experience based upon the first 3125 patients treated with meropenem. J Antimicrob Chemother 1995; 36Suppl. A: 207–23PubMedGoogle Scholar
  6. 6.
    Data on file, Bristol-Myers SquibbGoogle Scholar
  7. 7.
    Robinson DC, Cookson TL, Grisafe JA. Concentration guidelines for parenteral antibiotics in fluid-restricted patients. Drug Intell Clin Pharm 1987; 21: 985–9PubMedGoogle Scholar
  8. 8.
    Hitt CM, Nightingale CH, Quintiliani R, et al. Cost comparison of single daily iv doses of ceftriaxone versus continuous infusion of cefotaxime. Am Health Syst Pharm 1997; 54: 1614–8Google Scholar
  9. 9.
    VanDerLinde LP, Campbell RK. Guidelines for the intravenous administration of drugs. Drug Intell Clin Pharm 1977; 11: 30–55PubMedGoogle Scholar
  10. 10.
    Fish DN. Safety and cost of rapid iv injection of famotidine in critically ill patients. Am J Health Syst Pharm 1995; 52: 1889–94PubMedGoogle Scholar
  11. 11.
    Nowobilski-Vasilio A, Poole SM. Development and preliminary outcomes of a program for administering antimicrobials by i.v. push in home care. Am J Health Syst Pharm 1999; 56: 76–9Google Scholar

Copyright information

© Adis International Limited 1999

Authors and Affiliations

  • Paul G. Ambrose
    • 1
  • Khanh Q. Bui
    • 2
    • 3
  • Mark A. Richerson
    • 4
  • Richard Quintiliani
    • 5
    • 6
  • Charles Nightingale
    • 7
    • 8
  1. 1.Bristol-Myers Squibb CompanyPlainsboroUSA
  2. 2.Hartford HospitalHartfordConnecticu
  3. 3.University of Connecticut School of PharmacyStorrsUSA
  4. 4.Department of Defence Pharmacoeconomic CenterFt Sam HoustonUSA
  5. 5.Hartford HospitalHartford
  6. 6.University of Connecticut School of MedicineFarmingtonUSA
  7. 7.Hartford HospitalHartford
  8. 8.University of Connecticut School of PharmacyStorrsUSA

Personalised recommendations